Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B immunoglobulin
- Development stage
- Approved
- Lead developer
- Region Midtjylland
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular, Subcutaneous
01
Overview
Hepatitis B immunoglobulin (HBIG) is a polyclonal antibody preparation derived from human plasma containing high titers of antibodies against the hepatitis B surface antigen (anti-HBs). While traditionally utilized for post-exposure prophylaxis and the prevention of hepatitis B recurrence following liver transplantation, Region Midtjylland (specifically Aarhus University Hospital) has investigated its therapeutic potential for the treatment of chronic hepatitis B infection. The mechanism of action involves the binding and neutralization of circulating hepatitis B surface antigen (HBsAg), which is intended to reduce the viral burden and potentially alleviate the immune exhaustion characteristic of chronic HBV. In clinical trials led by Region Midtjylland, HBIG is typically administered intravenously, often in combination with nucleos(t)ide analogues, to evaluate its ability to induce a functional cure, defined by the sustained loss of HBsAg.
- Brand names
- AunativHepatect CPZutectraBayHep BNabi-HBHepaGam BHyperHEP B
- Other names
- HBIGanti-hepatitis B antibodiesanti-HBshepatitis B immune globulinanti-hepatitis B surface antigen antibodies
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis B immunoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B immunoglobulin.